AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00719420
Drug: Clarithromycin, Amoxicillin, Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
Trial: NCT04507321
Drug: GSK3640254 Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
Trial: NCT04507321
Drug: [14C]-GSK3640254 intravenous infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
Trial: NCT04507321
Drug: [14C]-GSK3640254 powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
Trial: NCT02010775
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
Trial: NCT03560232
Drug: Cefazolin + Gentamicin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT03560232
Drug: Clindamycin + Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT00674245
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg once daily for 4 weeks
Trial: NCT01044537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match PF-04937319 will be provided.
Trial: NCT00774189
Drug: clarithromycin 250 mg tablets
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00425308
Drug: Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00425308
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00845637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
Trial: NCT01647828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered IV
Trial: NCT00680706
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine (100 mg) in 50 ml D5W, x 2.
Trial: NCT01169753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet every morning for 2 weeks
Trial: NCT00789308
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulation
Trial: NCT00789308
Drug: CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell proliferation inhibitor
Trial: NCT00789308
Drug: Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00789308
Drug: Simulect® (Basiliximab) - at 2nd or 3rd transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal IL-2 receptor blocker
Trial: NCT00789308
Drug: Klexane® (Enoxaparinsodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation Prophylaxis
Trial: NCT00680706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5W (50 ml)
Trial: NCT01403363
Drug: use of fentanyl patch that was halved
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
Trial: NCT02462837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02233647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
Trial: NCT03570645
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: block with only ropivacaine
Trial: NCT03482180
Drug: KI1106 4g, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KI1106 4 Capsules
Trial: NCT03482180
Drug: Atorvastatin Calcium 20mg, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin Calcium 20mg
Trial: NCT01506622
Drug: Administration of fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
Trial: NCT01506622
Drug: Administration of saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be administered to control group at the end of anesthesia.
Trial: NCT01501448
Drug: Levonorgestrel and ethinylestradiol
RxNorm normalized name: levonorgestrel and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
Trial: NCT00627731
Drug: prednisolone (PSL)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSL 40 mg per day for 10 days
Trial: NCT01995032
Drug: 750 mg metformin and 7.5 g L-citrulline daily p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01995032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02837198
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01900704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02760069
Drug: Inhaled isopropyl alcohol
RxNorm normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
Trial: NCT02760069
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
Trial: NCT02882009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
Trial: NCT01777100
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
Trial: NCT02063022
Drug: Standard treatment (as per protocol ISG SSG III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
Trial: NCT02447315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03944460
Drug: Contraloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of capsules, drug substance or placebo without any excipients.
Trial: NCT01235962
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
Trial: NCT01235962
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
Trial: NCT01074138
Drug: KX2-391
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
Trial: NCT04073069
Drug: The R group
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Trial: NCT01754935
Drug: VX-509 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral tablet
Trial: NCT04344444
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablets provided as described in Arm C
Trial: NCT02048891
Drug: hCG trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03583489
Drug: APD421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg IV
Trial: NCT03583489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02486432
Drug: Levodopa/Carbidopa (Sinemet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
Trial: NCT00674700
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily for one year
Trial: NCT03490097
Drug: Simvastatin 10mg
RxNorm normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT02310568
Drug: PF-06372865.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
Trial: NCT02222974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02255604
Drug: Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4
Trial: NCT02255604
Drug: alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injection into a lymphnode
Trial: NCT02255604
Drug: 0.1 ml Isoton saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 injection into a lymphnode
Trial: NCT02301052
Drug: placebo topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo topical cream 2 cc twice daily for 3 weeks
Trial: NCT02301052
Drug: Anti-hemorrhoid topical cream
RxNorm normalized name: Americaine Hemorrhoidal Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
Trial: NCT04617509
Drug: Formulation B GS-248
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Trial: NCT00284271
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00284271
Drug: Procarbacine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03922555
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
Trial: NCT01269658
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Trial: NCT00840203
Drug: Mesalamine 4 gm/60 mL Rectal Enema
RxNorm normalized name: Mesalamine 4 GM/60 ML Rectal Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 4 gm/60 mL, single-dose
Trial: NCT04340401
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
Trial: NCT01179854
Drug: Remegal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug/ placebo
Trial: NCT01325415
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet
Trial: NCT01325415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01506167
Drug: Capecitabine/Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Trial: NCT01506167
Drug: Fluorouracil/Folinic Acid/Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Trial: NCT01506167
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was administered along with bevacizumab as part of standard first-line treatment
Trial: NCT01506167
Drug: Fluorouracil/Folinic Acid/Irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
Trial: NCT01506167
Drug: Fluorouracil +/- Folinic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
Trial: NCT00321802
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients take 40 mg of simvastatin per day for 6 months.
Trial: NCT00321802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02468115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of placebo
Trial: NCT00694785
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3
Trial: NCT00694785
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3
Trial: NCT00694785
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6
Trial: NCT00694785
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6
Trial: NCT03716024
Drug: PTK 0796
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
Trial: NCT00783003
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Long acting Beta 2 agonist (LABA)
Trial: NCT00783003
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
Trial: NCT00783003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo.
Trial: NCT01705639
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects receive the same dose of melatonin
Trial: NCT01803373
Drug: Treatment A (reference)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Trial: NCT01803373
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Trial: NCT03721653
Drug: L-Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/sqm iv over 2 hours day 1
Trial: NCT05806177
Drug: AD16 30mg、40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Trial: NCT05806177
Drug: AD16 Placebo 30mg、40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Trial: NCT00960778
Drug: nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
Trial: NCT02460302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository inserted vaginally
Trial: NCT00975650
Drug: Nasobol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal Testosterone (2 syringes), b.i.d.
Trial: NCT00975650
Drug: Androderm® (Positive Control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD administration
Trial: NCT01919125
Drug: IDX719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX719 supplied as 50 mg tablets.
Trial: NCT02025660
Drug: Mw, 0.3ml x three days sc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02025660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00035334
Drug: NC-503 (Anti-amyloidotic (AA) Agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02834507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT02834507
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing nebicapone 75 mg or 150 mg
Trial: NCT02834507
Drug: Comtan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing entacapone 200 mg
Trial: NCT02834507
Drug: Sinemet®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa/carbidopa (Sinemet®) dose patient used to take
Trial: NCT00817024
Drug: Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
Trial: NCT00817024
Drug: Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
Trial: NCT00817024
Drug: Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
Trial: NCT00500201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered orally by subjects.
Trial: NCT00622245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per oral doses, twice daily as capsules during 13 weeks
Trial: NCT03334734
Drug: PBTZ169
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 14 days
Trial: NCT03370601
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine 1 à 1,5 mg/kg
Trial: NCT03370601
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine 2 à 2.5mg/kg/j
Trial: NCT00299975
Drug: MaZiRenWan (MZRW) Median dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks